Rapid Micro Biosystems to Announce Fourth Quarter and Full Year 2022 Financial Results on March 3, 2023

Rhea-AI Summary

Rapid Micro Biosystems (Nasdaq: RPID) will announce its fourth quarter and full year 2022 financial results on March 3, 2023, before market opening. A webcast conference call is scheduled for 8:30 a.m. EST on the same day, with live access via the company's website. The company specializes in automation solutions for the healthcare sector, enhancing the manufacturing and quality control of products such as biologics and vaccines. Their flagship Growth Direct System facilitates faster, more accurate microbial quality control testing, improving operational efficiency and compliance in pharmaceutical manufacturing.

Positive

• Scheduled release of fourth quarter and full year 2022 financial results is expected to provide insights into business performance.
• The company's Growth Direct System modernizes and automates microbial quality control testing, potentially increasing demand.

Negative

• None.

LOWELL, Mass., Feb. 16, 2023 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, will release fourth quarter and full year 2022 financial results prior to the market open on Friday, March 3, 2023.

In conjunction with the release, the Company’s management team will host a webcast conference call at 8:30 a.m. EST on Friday, March 3, 2023.   The live and archived webcast will be accessible on the Company’s website here and will be available for replay for one year from the webcast date.

About Rapid Micro Biosystems

Rapid Micro Biosystems is an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products such as biologics, vaccines, cell and gene therapies, and sterile injectables. The Company’s flagship Growth Direct System automates and modernizes the antiquated, manual microbial quality control (“MQC”) testing workflows used in the largest and most complex pharmaceutical manufacturing operations across the globe. The Growth Direct System brings the quality control lab to the manufacturing floor, unlocking the power of MQC automation to deliver the faster results, greater accuracy, increased operational efficiency, better compliance with data integrity regulations, and quicker decision making that customers rely on to ensure safe and consistent supply of important healthcare products. The Company is headquartered and has U.S. manufacturing in Lowell, Massachusetts, with global locations in Lexington, Massachusetts, Switzerland, Germany, and the Netherlands. For more information, please visit www.rapidmicrobio.com or follow the company on Twitter at @rapidmicrobio or on LinkedIn.

FAQ

When will Rapid Micro Biosystems release its fourth quarter 2022 financial results?

Rapid Micro Biosystems will release its fourth quarter 2022 financial results on March 3, 2023, before market opening.

What time is the conference call for the financial results of RPID?

The conference call for Rapid Micro Biosystems' financial results is scheduled for 8:30 a.m. EST on March 3, 2023.

What products does Rapid Micro Biosystems focus on?

Rapid Micro Biosystems focuses on automation solutions for healthcare products such as biologics, vaccines, and sterile injectables.

What is the purpose of the Growth Direct System by RPID?

The Growth Direct System automates and modernizes microbial quality control testing workflows, enhancing efficiency and compliance in pharmaceutical manufacturing.